



Open End Certificate on AMEX BIOTECHNOLOGY INDEX

Underlying: WKN: ; Valor: ; ISIN: ; Reuters: .BTK; Bloomberg: BTK

Product Details

Underlying	AMEX BIOTECHNOLOGY INDEX
Conversion	10 : 1
Indicative Spot Price	USD
Issue Price	EUR 55,13
Reference Price of Underlying	USD 473,92
Redemption Amount	
Security No.	ISIN: CH0013812984 Valor: 1381298 WKN: 548311 Common Code: 14412875

Dates

Issue Date	01.03.02
Pricing Date	
Payment Date	05.03.02
Expiration Date	*
Redemption Date	5 Tage/5 Business Days

*The listing of these securities will be discontinued two trading days prior to maturity. From that date until maturity, only off-floor trading, with the issuer, will be possible.
**Spread: US trading hours 1.5 %; European trading hours 1.0 %

General Information

Issuer	UBS AG, London Branch
Lead manager	UBS Warburg AG, Frankfurt
Issue size	up to 1.000.000
Redemption	Cash Settlement in EUR on the Redemption date, minus a 0.15 % risk management fee, to be deducted for the first time on May 26, 2002, thereafter quarterly on August 26, November 26, February 26, and May 26 (in case that any of the dates is not a business day, the next following business day applies).

Payment amount = Payment Price in USD (= Index Closing Price x Ratio) x 1/(1,0015)ⁿ, transferred into EUR
n = number of Risk Management Fee calculation days since and including May 26, 2002; n1 being May 26, 2002

Trading Listing

Lot
Euwx

Sales
Restrictions
Clearing

Custody

9:00 - 22:00 Uhr/hours
Freiverkehr Frankfurt, Düsseldorf, Berlin, and Stuttgart
1 Certificate/s
Max.Spread: 5,00 EUR
Min.Size: 100 Certificate
U.S.A./U.S. persons; U.K.
Euroclear, Clearstream Banking AG, Clearstream Banking SA (Global Certificate at Clearstream Banking AG)
Clearstream Banking Frankfurt eligible

This document is issued by UBS Warburg AG, Stephanstrasse 14-16, 60313 Frankfurt („UBS Warburg“) a subsidiary of UBS AG, Zürich/Basel. It is subject to German law exclusively. This document is for information purposes only and is not intended to be an offer, recommendation or solicitation to buy or sell securities or derivatives and should not be treated as giving investment advice. Purchasers should determine for themselves the relevance of the information contained in this document and the decision to purchase any of the securities or derivatives should be based upon such investigation as they themselves deem necessary. This document is based on information obtained from sources believed to be reliable but no independent verification has been made, nor is its accuracy or completeness guaranteed. The product related information in this document is based on the selling prospectus, which is solely legally authoritative. UBS Warburg accepts no liability for any loss or damage of any kind arising out of the use of this document. UBS Warburg, and its related companies and/or its directors, officers and employees may take positions in, and may make purchases and/or sales as principal or agent or act as market-maker in the securities or related financial instruments discussed herein. This security may not be offered, sold or delivered within the United States or to U.S. persons or to persons who are UK private customers. This document may not be reproduced or distributed in any manner without the written permission of UBS Warburg. UBS Warburg accepts no liability for actions of third parties regarding this.
Sources: Company/Index Description: Bloomberg; Chart: Reuters

Contact:


UBS Warburg AG
Investment Products
Stephanstrasse 14-16
60313 Frankfurt am Main
Germany

Phone: +49 (0) 69 1369 - 8630 / - 8636
Fax: +49 (0) 69 1369 - 8631
Internet: www.ubswarburg.com/keyinvest
Reuters : UBSDEEW02



Open End Certificate on AMEX BIOTECHNOLOGY INDEX

The AMEX Biotechnology Index^{SM*} is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The index was developed with a base level of 200 as of October 18, 1991.



Issuer's Call Right: The Issuer has an annual right, on March 5, for the first time on March 5, 2005 ("Notice Date"), to call the Open End Certificates for early redemption after notice has been published to that effect. The termination period is 2 years. The termination will become effective as of close of business on March 5 of the relevant year.

Investor's Exercise Right: In addition to the possibility to sell the Open End Certificates at any time on the above mentioned stock exchanges, each Investor has an annual right to exercise his Open End Certificates (notice to be received no later than 10:00 am, on March 5, Frankfurt time) for a value of 1/10 of the current conversion value at the time of the exercise. The exercise will become effective as of close of business on March 5 of the relevant year.

(In case that any of the dates is not a business day, the next following business day applies).

The valuation day shall be March 5 of the relevant year.

*The AMEX Biotechnology IndexSM (the "Index") is sponsored by, and a service mark of, the American Stock Exchange (the "Exchange") and is being used with the permission of the Exchange. The Exchange in no way sponsors, endorses or is otherwise involved in this Transaction and it disclaims any liability to any party for any inaccuracy in the data on which the Index is based, for any mistakes, errors, or omissions in the calculation and/or dissemination of the Index, or for the manner in which it is applied in connection with this Transaction.

This document is issued by UBS Warburg AG, Stephanstrasse 14-16, 60313 Frankfurt („UBS Warburg“) a subsidiary of UBS AG, Zürich/Basel. It is subject to German law exclusively. This document is for information purposes only and is not intended to be an offer, recommendation or solicitation to buy or sell securities or derivatives and should not be treated as giving investment advice. Purchasers should determine for themselves the relevance of the information contained in this document and the decision to purchase any of the securities or derivatives should be based upon such investigation as they themselves deem necessary. This document is based on information obtained from sources believed to be reliable but no independent verification has been made, nor is its accuracy or completeness guaranteed. The product related information in this document is based on the selling prospectus, which is solely legally authoritative. UBS Warburg accepts no liability for any loss or damage of any kind arising out of the use of this document. UBS Warburg, and its related companies and/or its directors, officers and employees may take positions in, and may make purchases and/or sales as principal or agent or act as market-maker in the securities or related financial instruments discussed herein. This security may not be offered, sold or delivered within the United States or to U.S. persons or to persons who are UK private customers. This document may not be reproduced or distributed in any manner without the written permission of UBS Warburg. UBS Warburg accepts no liability for actions of third parties regarding this. Sources: Company/Index Description: Bloomberg; Chart: Reuters

Certificates

Certificates are a group of products, which replicate the performance of the underlying. Certificates give the investor the possibility to be diversified with low administrative costs and small investment amounts. The risk of loss is limited to the invested capital.

Contact:

UBS Warburg AG
Investment Products
Stephanstrasse 14-16
60313 Frankfurt am Main
Germany

Phone: +49 (0) 69 1369 - 8630 / - 8636
Fax: +49 (0) 69 1369 - 8631
Internet: www.ubswarburg.com/keyinvest
Reuters : UBSDEEW02